To calculate the prevalence rates and costs of common conditions using medical and pharmacy claims from a commercially insured US population in 2010. METHODS: This retrospective cohort analysis used administrative claims data from 14 major US health plans. Patients had Ն1 claim for a targeted condition (identified by ICD-9 or GPI codes) from 01/01/2010 through 12/31/2010. Descriptive statistics included means and relative frequencies. Costs reported for patients with 12 months continuous eligibility and presented as annualized per patient per month (PMPM) costs to include all patients regardless of length of eligibility. Patients were required to have Ն1 day of eligibility. RESULTS: The 10 most prevalent conditions: hyperlipidemia (13.9%), hypertension (13.6%), allergic rhinitis (5.6%), diabetes (4.8%), COPD/COPD-associated conditions (4.8%), diabetes without complications (4.7%), depression (other than major depression and bipolar disorder) 4.0%, osteoarthritis (3.8%), asthma (3.6%), osteoporosis/osteopenia (2.8%). Allergic rhinitis was most common among those Ն34 yrs; hyperlipidemia among patients aged 35-64 yrs; hypertension among patients Ն65 yrs. Highest average (PMPM) medical costs were: bone cancer $82,173 ($119,528) 14,198 ($14,682); leukemia $9,050 ($$9,983); psoriatic arthritis $8,035 ($8,291); brain cancer $7,766 ($8,861); ankylosing spondylitis $5,989 ($6,324); bone cancer $5,211 ($5,498); CNS cancer $4,697 ($5,748); renal cancer $4,620 ($5,507). CONCLUSIONS: Hyperlipidemia and hypertension were more than twice as prevalent as the next most prevalent condition in 2010; this pattern held for males and females and generally held across geographic regions of the U.S. Consistent with prior research, cancers and cancer treatments were consistently ranked among the most expensive for health plans in 2010. 
OBJECTIVES:
To calculate the prevalence rates and costs of common conditions using medical and pharmacy claims from a commercially insured US population in 2010. METHODS: This retrospective cohort analysis used administrative claims data from 14 major US health plans. Patients had Ն1 claim for a targeted condition (identified by ICD-9 or GPI codes) from 01/01/2010 through 12/31/2010. Descriptive statistics included means and relative frequencies. Costs reported for patients with 12 months continuous eligibility and presented as annualized per patient per month (PMPM) costs to include all patients regardless of length of eligibility. Patients were required to have Ն1 day of eligibility. RESULTS: The 10 most prevalent conditions: hyperlipidemia (13.9%), hypertension (13.6%), allergic rhinitis (5.6%), diabetes (4.8%), COPD/COPD-associated conditions (4.8%), diabetes without complications (4.7%), depression (other than major depression and bipolar disorder) 4.0%, osteoarthritis (3.8%), asthma (3.6%), osteoporosis/osteopenia (2.8%). Allergic rhinitis was most common among those Ն34 yrs; hyperlipidemia among patients aged 35-64 yrs; hypertension among patients Ն65 yrs. Highest average (PMPM) medical costs were: bone cancer $82,173 ($119,528); CNS cancer $81,101 ($110,829); brain cancer $74,055 ($187,244) ; subarachnoid hemorrhage $67,324 ($161,164) ; intracerebral hemorrhage $60,968 ($203,551) ; multiple myeloma $43,495 ($68,614); leukemia $41,873 ($68,703) ; lung cancer $40,691 ($97,279) ; colorectal cancer $34,498 ($65,025) . Highest average (PMPM) pharmacy costs were: multiple myeloma $17,567 ($18,907) ; multiple sclerosis $14,198 ($14,682) ; leukemia $9,050 ($$9,983); psoriatic arthritis $8,035 ($8,291); brain cancer $7,766 ($8,861); ankylosing spondylitis $5,989 ($6,324); bone cancer $5,211 ($5,498); CNS cancer $4,697 ($5,748); renal cancer $4,620 ($5,507) . CONCLUSIONS: Hyperlipidemia and hypertension were more than twice as prevalent as the next most prevalent condition in 2010; this pattern held for males and females and generally held across geographic regions of the U.S. Consistent with prior research, cancers and cancer treatments were consistently ranked among the most expensive for health plans in 2010. 
PHS8 USE OF HEALTH CARE ADMINISTRATIVE DATABASES TO ESTIMATE INCIDENCE OF FOOT COMPLICATIONS IN DIABETES PATIENTS

OBJECTIVES:
Foot complications (e.g. infections, abscesses) are common in patients with diabetes mellitus (DM) and are associated with high morbidity and risk of lower extremity amputation. The objective of this analysis was to estimate the incidence of foot complications in patients with a diabetes diagnosis. METHODS: DM population in Lombardy Region (Italy) was identified through a data warehouse (DENALI), matching with probabilistic record linkage demographic, clinical and economic data of different Healthcare Administrative databases. We selected individuals with diabetes diagnosis prior to December 31, 2000 (hospital discharge with an IDC-9 CM code 250.XX, and/or two consecutive prescriptions of drugs for diabetes (ATC code A10XXXX) within one year, and/or an exemption from copayment health care costs specific for DM). From this cohort, we detected patients requiring at least one hospitalization for toe and foot complications (e.g. ICD-9 CM 682.7, "Other cellulitis and abscess-Foot") in the next 9 years of follow-up. RESULTS: Over the follow-up period, 5,096 of the 1,322,686 hospitalizations of DM patients (0.39%), were attributable to foot and toe complications. We individuated 3,404 patients (1.09% of the overall diabetes population; Nϭ312,223) with at least one hospitalization for foot and toe complications (males: 64.72%, mean age: 64.64 years). The most frequent conditions were lower limb amputations (ICD-9 CM: V497.X; Nϭ1,729 patients), cellulitis and abscesses of foot (ICD-9 CM: 682.7; Nϭ976 patients) and cellulitis and abscesses of toe (ICD-9 CM: 681.1; Nϭ783 patients). Considering the overall observation period (831 million days, 7.29 years per patient), incidence rates were 0.76, 0.43 and 0.35 events per 1,000 pts-year, for amputations, cellulitis or abscesses of the foot, cellulitis or abscesses of the toe, respectively. CONCLUSIONS: Administrative database analysis is an efficient tool to track foot and toe serious complications, as only events requiring hospitalization can be detected with this methodology. 
PHS9 REGIONAL AND AGE DISTRIBUTION EVALUATION OF THE OUTPATIENT CARE PHYSIOTHERAPY SERVICES FOR HIGH INCIDENCE TRAUMATIC INJURIES
OBJECTIVES:
To evaluate the most frequent outpatient care physiotherapy services provided for trauma patients, based on age and regional distribution. METHODS: Data were derived from the countrywide database of Hungarian Health Insurance Administration (HHIA), based on official reports of outpatient care institutes. The 151 different types of treatment codes are listed in the chapter of the Guidelines of HHIA for 'Physiotherapists, massage-therapists, conductors and other physiotherapy practices'. Of the physiotherapeutic services provided for trauma patients, the knee and lower leg injuries (ICD code S80-89) occurred with the highest incidence. Data collected from the year 2008 were further analyzed based on the distribution among the 7 different Hungarian regions and based on age distribution, set to 5 years intervals. RESULTS: The total number of the provided 151 different types WHO-classified physiotherapy services was 29045736 in the year of 2008; 3188650 of them with the ICD code group S00-S99 with the highest incidence: 713898 of services for knee and lower leg injuries (S80 -S89). The highest number of physiotherapy treatment in total of 86048 cases was provided for patients in the age group 30 to 34, followed by age group of 35 to 39 with 77903 cases. The average number of cases was 71.17/1000 persons. Injuries related treatments occurred with the highest incidence in the Central-Hungarian region (81.07 cases/ 1000 population) and with the lowest incidence in the Western-Transdanubian region (62.52 cases/1000 population). CONCLUSIONS: In case of the traumatic injuries, the highest demand of the outpatient care physiotherapy services occurred for knee and lower leg injured patients. The differences of the incidences (calculated per 1000 persons) in the regional distributions require further studies.
PHS10 HBA1C TESTING FREQUENCY IN PRIMARY CARE DIABETES PATIENTS IN GERMANY AND IN THE UK
Kostev K, Grunow S, Rockel T IMS Health, Frankfurt am Main, Germany OBJECTIVES: The HbA1c test is a lab test, which reveals average blood glucose over a period of two to three months. Tight blood glucose control could reduce the risk of diabetes related complications. Expert opinion recommends 6-monthly HbA1c testing in stable and 3-monthly testing in type 1 and unstable type 2 diabetes patients. Moreover, HbA1c should be measured more frequently for patinets whose therapy is changing. The aim of this study was to measure the quality of diabetic care as indicated by HbA1c testing frequency and to compare the frequency of HbA1c testing in primary care diabetes patients in Germany (DE) and UK. METHODS: Computerized data on lab values (IMS Disease Analyzer Multi-Country Solution, 01/2011-12/2011) from general medicine practices throughout DE and UK have been analysed and compared. This data warehouse includes the complete diagnosis and therapy relevant information on diabetes patients in several countries. 159,031 T2D patients and 1,910 T1D patients from 1,001 GP practices in Germany and 34,375 T2D patients and 1.506 T1D patients from 104 GP practices in UK were included. RESULTS: 53.1% of T2D patients and 42.0% of T1D patients in Germany, 87.0% of T2D patients and 69.1% of T1D patients in UK had at least one HbA1c testing in the observation time. In Germany there were 1.5 HbA1c tests per year in T2D patients and 1.1 tests per year in T1D patients. In UK T2D patients have in average 3.1, T1D patients 2.0 HbA1c tests in 2011. CONCLUSIONS: The study revealed that HbA1c testing was underused in both T1D and T2D patients. Improvement is needed in the utilization of HbA1c testing among most diabetes patients in Germany and UK. HbA1c tests should be obtained routinely in all persons with diabetes, for the blood glucose control documentation and as part of continuing care. Physical function was measured via 20-foot walking speed [WS] in meters/second, having difficulty walking up 10 steps (yes/no), and having difficulty standing up from armless chairs (yes/no). Muscle strength was measured via the isokinetic quadriceps strength in newtons. Two study cohorts were constructed based on age and gender (10 groups) adjusted muscle strength (high strength ϭ above the median within each age and gender group). Demographics, comorbidities, and body mass index (BMI) were compared between the high and low strength groups. The association between high/low muscle strength and 20-foot WS was analyzed via multiple linear regression that utilized survey strata and weighting and controlled for between-group differences in demographics, BMI, and comoribidites. Logistic regressions were employed to examine the relationship between having difficulty walking up 10 steps or standing up from armless chairs and high/low muscle strength, respectively. RESULTS: The study included 646 individuals with 320 in the high and 326 in the low strength cohorts. More individuals with low muscle strength had diabetes, arthritis, and osteoporosis than those with high muscle strength. Mean BMI was also higher in the high strength cohort. Controlling for differences in demographics, comorbidities, and BMI, individuals in the high strength cohort had significantly faster 20-foot WS speed (0.10, pϽ0.05) and were less likely to have difficulty standing up from armless chairs (Odds Ratio ϭ 0.32, pϽ0.05) compared with those in the low strength cohort. CONCLUSIONS: Among individuals aged 50 and above in the US, high muscle strength is positively correlated with WS but negatively correlated with having difficulty standing up from armless chairs. pertension, serum cholesterol, and diabetes mellitus decreases the risk of Parkinson's disease (PD). We therefore examined the epidemiologic association of PD with hypertension, serum total cholesterol, and diabetes mellitus by conducting a detailed meta-analysis of all studies published regarding this subject. METHODS: A systematic comprehensive literature search was performed using PubMed, EMBASE, and CINAHL (until March 2012) for observational cohort and case-control studies using relevant keywords. Pooled relative risk (RR) was calculated using random effects model. Pre specified subgroup analysis was performed to assess the source of heterogeneity, according to study design, number of covariates adjusted and adjusted for BMI and cardiovascular diseases. Subgroup and sensitivity analysis were also done. Heterogeneity and publication bias were also assessed. RESULTS: 24 studies were included in the analysis. The pooled risk ratio of PD due to hypertension (nϭ8) was 0.78 (95% CI, 0.67-0.92, I2ϭ71.85%), due to high serum cholesterol (nϭ7) was 0.95 (95% CI, 0.77-1.17, I2ϭ 75.86%), and due to diabetes (nϭ14) was 0.94 (95% CI, 0.76-1.16, I2ϭ 89.62%). Subgroup analysis showed a significant difference in effect estimate pooled by cohort and case-control studies (PinteractionϽ0.001). Pooled analysis of cohort studies for diabetes showed a pooled risk ratio of 1.34 (95%CI, 1.12-1.60, I2ϭ76.77%). We found no significant difference in any subgroup analysis. CONCLUSIONS: We found evidence of significant inverse associations of hypertension, hypercholesterolemia, and diabetes mellitus with the risk of PD. Further well-designed investigations of the association of vascular risk factors with the risk of PD are needed, particularly large-scale prospective studies. 
PHS11 RELATIONSHIP BETWEEN PHYSICAL FUNCTION AND MUSCLE STRENGTH IN THE UNITED STATES ELDERLY POPULATION
PHS12
META-ANALYSIS OF PARKINSON'S DISEASE RISK WITH HYPERTENSION, SERUM TOTAL CHOLESTEROL, AND DIABETES MELLITUS
HEALTH SERVICES -Cost Studies
PHS13 COSTS ANALYSIS OF A MOBILE PHONE TELEMONITORING SYSTEM FOR GLYCAEMIC CONTROL IN PATIENTS WITH DIABETES MELLITUS (DM) IN SPAIN: PRELIMINARY RESULTS
OBJECTIVES:
Technological developments allow remote monitoring of patients and improve diabetes care. A mobile phone telemonitoring system (TM) might improve the ability of DM patients to engage in treatment. The objective is to estimate the annual costs that implementing a TM for glycaemic control in DM patients might represent to the National Health System and to society in Spain. METHODS: First, a systematic review of the literature was conducted to determine cost drivers in DM TM. Electronic databases were searched to identify national and international clinical and economic articles, published between January, 2001 and December, 2011, reporting on the clinical benefits, health resources used and costs associated to DM TM. Second, based on the data gathered, and adapted for Spain, and on the assumption that TM favors treatment compliance, a mathematical model was applied to determine the variation in costs associated to macro and micro DM complications risk reduction derived from hypothetically reaching 100% DM treatment compliance in groups of patients: compliant, noncompliant and complications are undiagnosed. RESULTS: A total of 3.539 articles were identified; 48 were reviewed. TM decreases emergency visits (83%), disease related hospital admissions (75%), length of hospital admission (51%), visits to the outpatient clinic (40%) and to the specialist (19%). Reduction of indirect costs reaches 120.82 € per DM patient/year due to less travel expenses (-6 .30 €/visits) and productivity gain (-54 €/visits) . Assuming that 100% of uncompliant DM patients become compliant (n ϭ 1,550,634 patients) costs associated to macro-and micro-vascular complications decreases by 5,500 € (€, 2011) million per year. Higher cost reductions are obtained in the most prevalent vascular complications. CONCLUSIONS: These preliminary results show that TM in DM patients reduces direct and indirect costs. Significant costs reduction can be reached if DM treatment compliance is improved with TM in Spain. 
PHS14 CLINICAL AND ECONOMIC ANALYSIS OF "MOLICARE® PREMIUM EXTRA SOFT" DIAPERS EFFICIENT APPLICATION FOR DERMATITIS AND PRESSURE ULCERS' PROPHYLAXIS FOR IMMOBILE URINARY-INCONTINENT PATIENTS
OBJECTIVES:
To carry out a clinical-economic analysis of MoliCare® Premium extra soft diapers application efficiency for contact dermatitis* and pressure ulcers prophylaxis with immobile urinary-incontinent patients. METHODS: Estimation of typical management practice with immobile urinary-incontinent patients' having developed contact dermatitis* or pressure ulcers was performed by means of experts' questioning. Only direct medical costs were taken into account in the research. A comparative clinical-economic analysis was performed using Markov's model. A sensitivity analysis was performed taking into account retail and wholesale prices for absorbing means and skin care agents. RESULTS: Twenty weeks' total costs calculated with Markov's model use for contact dermatitis* and 1-4 degree pressure ulcers prophylaxis and treatment with one immobile urinaryincontinent patient with absorbent means and skin care agents' application were 5508 € in retail prices and 5276 € in wholesale prices; without their application the costs were 7 446 €. Overall this Analysis shows that medical-prophylactic institutions' costs for contact dermatitis* and pressure ulcers' prophylaxis and treatment with one immobile urinary-incontinent patient without absorbing means and skin care agents applying are considerably higher (by 41%) than when they are applied. At the same time indirect costs including linen disinfection, washing, drying and ironing were not taken into account and such costs can increase a costs' total figure. CONCLUSIONS: Absorbent means and skin care agents' application for contact dermatitis and pressure ulcers prophylaxis and treatment with immobile urinary-incontinent patients is a dominant technique and cost efficacy of using absorbent means and skin care agents was demonstrated. The Branch standard "Patients' management protocol. Pressure ulcers" (2002) 
To quantify the financial effects of the introduction of a recommendation for rotavirus vaccination in Saxony, Germany, in 2008 using a retrospective data analysis. Special emphasis is given to the herd effect. METHODS: We analyzed the costs of rotavirus infection between 2007 and 2010 based on 360.000 observations from the AOK Plus of children under 5 years for Saxony. To investigate the cost impact of the regional recommendation, we compared the associated costs of the expected annual RVGE cases derived from 2005 when rotavirus vaccination was not yet available, with the actual annual number of RVGE cases, vaccinations and associated costs per age cohort. A decrease in RVGE cases in not vaccinated cohorts was attributed to herd effect. We make distinction between in-and outpatient cases, societal and SHI perspective as well as different age groups. RESULTS: Given that the vaccination rate has increased from 5% to 61% in the observed period, we obtained following estimates: the mean total cost reduction per year attributable to introducing a recommendation for rotavirus vaccination is 4.5 million € (2.4 million €) from the societal (SHI) perspective. The mean cost savings of vaccination per avoided case rise from 572 € (291 €) in 2007 to 718 € (375 €) in 2010. The overall share of outpatient costs is about 72% (60%). About 45% of the total savings is attributable to herd effect. The herd effect per avoided case decreases over time while immunity increases. CONCLUSIONS: A recommendation for rotavirus vaccination in Saxony turns out to be cost saving from the SHI as well as the societal perspective. This is mainly attributed to the herd effect being present when having high vaccination rates.
